GPhA’s Neas Preaches Vigilance Against Reopening Hatch-Waxman Act
After five months on the job, Generic Pharmaceutical Association President and CEO Ralph Neas is optimistic about the industry’s future but prepared to do battle against any efforts to re-work the landmark 1984 law. Preparations include establishing a new non-profit arm, the Affordable Medicine Research Institute, which will focus on research and public education about generics and biosimilars.
You may also be interested in...
GPhA’s Deficit Reduction Proposals Focus On Medicare Low-Income Subsidy, REMS Policies
In letters to congressional leaders, generic drug trade group outlines six proposals that it says would save the government billions of dollars and lessen the impact of sequestration cuts.
GPhA’s Goals For 2013: Smooth GDUFA Implementation, Workable Biosimilar Pathway
The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.
Generic Industry’s Drug Shortage Program Creates Trigger Mechanism For FDA
GPhA enlists IMS Health for analysis of production data to help FDA devise roadmap to ameliorate shortages when a company plans to halt or interrupt a drug’s manufacture.